Skip to main content
Erschienen in: Current Treatment Options in Gastroenterology 4/2017

24.10.2017 | Motility (H Parkman and R Schey, Section Editors)

Diabetes Mellitus and the Colon

verfasst von: Marc S. Piper, MD, MSc, Richard J. Saad, MD, MS, FACG

Erschienen in: Current Treatment Options in Gastroenterology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Opinion statement

Diabetes mellitus (DM) can affect the structure and function of the colon promoting commonly encountered lower gastrointestinal symptoms such as constipation, diarrhea, abdominal distention, bloating, and abdominal pain. Specific colonic disorders for which adults with DM are at greater risk include chronic constipation, enteropathic diarrhea, colorectal cancer (CRC), inflammatory bowel disease, microscopic colitis, and Clostridium difficile colitis. Smooth muscle structure and function, density of the interstitial cells of Cajal, and the health and function of the autonomic and enteric nerves of the colon are all potential affected by DM. These effects can in turn lead to alterations in colon motility, visceral sensation, immune function, endothelial function, and the colonic microbiome. The evaluation and treatment for slow transit constipation as well as pelvic floor dysfunction should be considered when constipation symptoms are refractory to initial treatment measures. DM-related medications and small bowel conditions such as celiac disease and small intestinal bowel overgrowth should be considered and excluded before a diagnosis of enteropathic diarrhea is made. Given the higher risk of CRC, adults with DM should be appropriately screened and may require a longer bowel preparation to ensure an adequate evaluation.
Literatur
2.
Zurück zum Zitat Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–49.CrossRefPubMed Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–49.CrossRefPubMed
3.
Zurück zum Zitat Horváth VJ, Putz Z, Izbéki F, et al. Diabetes-related dysfunction of the small intestine and the colon: focus on motility. Curr Diab Rep. 2015;15(11):94.CrossRefPubMed Horváth VJ, Putz Z, Izbéki F, et al. Diabetes-related dysfunction of the small intestine and the colon: focus on motility. Curr Diab Rep. 2015;15(11):94.CrossRefPubMed
4.
Zurück zum Zitat Bril F, Cusi K. Nonalcoholic fatty liver disease. Endocrinol Metab Clin N Am. 2016;45(4):765–81.CrossRef Bril F, Cusi K. Nonalcoholic fatty liver disease. Endocrinol Metab Clin N Am. 2016;45(4):765–81.CrossRef
6.
Zurück zum Zitat Feldman M, Schiller LR. Disorders of gastrointestinal motility associated with diabetes mellitus. Ann Intern Med. 1983;98:378–84.CrossRefPubMed Feldman M, Schiller LR. Disorders of gastrointestinal motility associated with diabetes mellitus. Ann Intern Med. 1983;98:378–84.CrossRefPubMed
7.
Zurück zum Zitat Bytzer P, Talley NG, Leemon M, et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 1500 adults. Arch Intern Med. 2001;161:1989–96.CrossRefPubMed Bytzer P, Talley NG, Leemon M, et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 1500 adults. Arch Intern Med. 2001;161:1989–96.CrossRefPubMed
8.
Zurück zum Zitat Maisey A. A practical approach to gastrointestinal complications of diabetes. Diab Ther. 2016;7:379–86.CrossRef Maisey A. A practical approach to gastrointestinal complications of diabetes. Diab Ther. 2016;7:379–86.CrossRef
9.
Zurück zum Zitat Yarandi SS, Srinivasan S. Diabetic gastrointestinal motility disorders and the role of the enteric nervous system: current status and future directions. Neurogastroenterol Motil. 2014;26(5):611–24.CrossRefPubMedPubMedCentral Yarandi SS, Srinivasan S. Diabetic gastrointestinal motility disorders and the role of the enteric nervous system: current status and future directions. Neurogastroenterol Motil. 2014;26(5):611–24.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Domènech A, Pasquinelli G, De Giorgio R, et al. Morphofunctional changes underlying intestinal dysmotility in diabetic RIP-I/hIFNβ transgenic mice. Int J Exp Pathol. 2011;92(6):400–12.CrossRefPubMedPubMedCentral Domènech A, Pasquinelli G, De Giorgio R, et al. Morphofunctional changes underlying intestinal dysmotility in diabetic RIP-I/hIFNβ transgenic mice. Int J Exp Pathol. 2011;92(6):400–12.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Du F, Wang L, Qian W, et al. Loss of enteric neurons accompanied by decreased expression of GDNF and PI3K/Akt pathway in diabetic rats. Neurogastroenterol Motil. 2009;21(11):1229–e114.CrossRefPubMed Du F, Wang L, Qian W, et al. Loss of enteric neurons accompanied by decreased expression of GDNF and PI3K/Akt pathway in diabetic rats. Neurogastroenterol Motil. 2009;21(11):1229–e114.CrossRefPubMed
12.
Zurück zum Zitat Furlan MMDP, Molinari SL, Neto M, et al. Morphoquantitative effects of acute diabetes on the myenteric neurons of the proximal colon of adults rats. Arq Neuro Psiquiatr. 2002;60(3):576–81.CrossRef Furlan MMDP, Molinari SL, Neto M, et al. Morphoquantitative effects of acute diabetes on the myenteric neurons of the proximal colon of adults rats. Arq Neuro Psiquiatr. 2002;60(3):576–81.CrossRef
13.
Zurück zum Zitat Nakahara M, Isozaki K, Hirota S, et al. Deficiency of KIT-positive cells in the colon of patients with diabetes mellitus. J Gastroenterol Hepatol. 2002;17(6):666–70.CrossRefPubMed Nakahara M, Isozaki K, Hirota S, et al. Deficiency of KIT-positive cells in the colon of patients with diabetes mellitus. J Gastroenterol Hepatol. 2002;17(6):666–70.CrossRefPubMed
14.
Zurück zum Zitat Dong L, Liang X, Sun B, et al. Impairments of the primary afferent nerves in a rat model of diabetic visceral hyposensitivity. Mol Pain. 2015;11:74.CrossRefPubMedPubMedCentral Dong L, Liang X, Sun B, et al. Impairments of the primary afferent nerves in a rat model of diabetic visceral hyposensitivity. Mol Pain. 2015;11:74.CrossRefPubMedPubMedCentral
15.
16.
Zurück zum Zitat Azpiroz F, Malagelada C. Diabetic neuropathy in the gut: pathogenesis and diagnosis. Diabetologia. 2016;59(3):404–8.CrossRefPubMed Azpiroz F, Malagelada C. Diabetic neuropathy in the gut: pathogenesis and diagnosis. Diabetologia. 2016;59(3):404–8.CrossRefPubMed
17.
Zurück zum Zitat Celik AF, Osar Z, Damci T, et al. How important are the disturbances of lower gastrointestinal bowel habits in diabetic outpatients? Am J Gastroenterol. 2001;96(4):1314–6.CrossRefPubMed Celik AF, Osar Z, Damci T, et al. How important are the disturbances of lower gastrointestinal bowel habits in diabetic outpatients? Am J Gastroenterol. 2001;96(4):1314–6.CrossRefPubMed
18.
Zurück zum Zitat Enck P, Rathmann W, Spiekermann M, et al. Prevalence of gastrointestinal symptoms in diabetic patients and non-diabetic subjects. Z Gastroenterol. 1994;32:637–41.PubMed Enck P, Rathmann W, Spiekermann M, et al. Prevalence of gastrointestinal symptoms in diabetic patients and non-diabetic subjects. Z Gastroenterol. 1994;32:637–41.PubMed
19.
Zurück zum Zitat Maleki D, Locke GR, Camilleri M, et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med. 2000;160(18):2808–16.CrossRefPubMed Maleki D, Locke GR, Camilleri M, et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med. 2000;160(18):2808–16.CrossRefPubMed
20.
Zurück zum Zitat Maleki D, Camilleri M, Burton DD, et al. Pilot study of pathophysiology of constipation among community diabetics. Dig Dis Sci. 1998;43(11):2373–8.CrossRefPubMed Maleki D, Camilleri M, Burton DD, et al. Pilot study of pathophysiology of constipation among community diabetics. Dig Dis Sci. 1998;43(11):2373–8.CrossRefPubMed
21.
22.
Zurück zum Zitat • Prasad VGM, Abraham P. Management of chronic constipation in patients with diabetes mellitus. Indian J Gastroenterol. 2017;36(1):11–22. A recent and comprehensive review that discusses the treatment of constipation in diabeticsCrossRefPubMed • Prasad VGM, Abraham P. Management of chronic constipation in patients with diabetes mellitus. Indian J Gastroenterol. 2017;36(1):11–22. A recent and comprehensive review that discusses the treatment of constipation in diabeticsCrossRefPubMed
23.
Zurück zum Zitat Bharucha AE, Pemberton JH, Locke GR III. American Gastroenterological Association technical review on constipation. Gastroenterology. 2013;144(1):218–38.CrossRefPubMedPubMedCentral Bharucha AE, Pemberton JH, Locke GR III. American Gastroenterological Association technical review on constipation. Gastroenterology. 2013;144(1):218–38.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Rao SSC, Bharucha AE, Chiarioni G, et al. Anorectal disorders. Gastroenterology. 2016;150(6):1430–42.CrossRef Rao SSC, Bharucha AE, Chiarioni G, et al. Anorectal disorders. Gastroenterology. 2016;150(6):1430–42.CrossRef
25.
Zurück zum Zitat Rao SSC, Camilleri M, Hasler WL, et al. Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterol Motil. 2011;23(1):8–23.CrossRefPubMed Rao SSC, Camilleri M, Hasler WL, et al. Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterol Motil. 2011;23(1):8–23.CrossRefPubMed
26.
Zurück zum Zitat Panesar PS, Kumari S. Lactulose: production, purification and potential applications. Biotechnol Adv. 2001;29(6):940–8.CrossRef Panesar PS, Kumari S. Lactulose: production, purification and potential applications. Biotechnol Adv. 2001;29(6):940–8.CrossRef
27.
Zurück zum Zitat Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365:527–36.CrossRefPubMed Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365:527–36.CrossRefPubMed
28.
Zurück zum Zitat Miner PB Jr, Koltun WD, Wiener GJ, et al. A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation. Am J Gastroenterol. 2017;112(4):613–21.CrossRefPubMed Miner PB Jr, Koltun WD, Wiener GJ, et al. A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation. Am J Gastroenterol. 2017;112(4):613–21.CrossRefPubMed
29.
Zurück zum Zitat •• Christie J, Shroff S, Shahnavaz N, et al. A randomized, double-blind, placebo-controlled trial to examine the effectiveness of lubiprostone on constipation symptoms and colon transit time in diabetic patients. Am J Gastroenterol. 2017;112(2):356–64. Randomized, controlled trial (lubiprostone versus placebo) which demonstrates the effectiveness of lubiprostone in improving colonic transit time and bowel function in diabetic patients.CrossRefPubMed •• Christie J, Shroff S, Shahnavaz N, et al. A randomized, double-blind, placebo-controlled trial to examine the effectiveness of lubiprostone on constipation symptoms and colon transit time in diabetic patients. Am J Gastroenterol. 2017;112(2):356–64. Randomized, controlled trial (lubiprostone versus placebo) which demonstrates the effectiveness of lubiprostone in improving colonic transit time and bowel function in diabetic patients.CrossRefPubMed
30.
Zurück zum Zitat Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344–54.CrossRefPubMed Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344–54.CrossRefPubMed
31.
Zurück zum Zitat •• Bharucha AE, Low P, Camilleri M, et al. A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation. Gut. 2013;62(5):708–15. Randomized, controlled trial (pyridostigmine versus placebo) which shows improvement in colonic transit time and bowel function in diabetic patients (without defecatory disorders) on pyridostigmine.CrossRefPubMed •• Bharucha AE, Low P, Camilleri M, et al. A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation. Gut. 2013;62(5):708–15. Randomized, controlled trial (pyridostigmine versus placebo) which shows improvement in colonic transit time and bowel function in diabetic patients (without defecatory disorders) on pyridostigmine.CrossRefPubMed
32.
Zurück zum Zitat Lysy J. The prevalence of chronic diarrhea among diabetic patients. Am J Gastroenterol. 1999;94(8):2165–70.CrossRefPubMed Lysy J. The prevalence of chronic diarrhea among diabetic patients. Am J Gastroenterol. 1999;94(8):2165–70.CrossRefPubMed
33.
Zurück zum Zitat Schiller LR, Pardi DS, Sellin JH. Chronic diarrhea: diagnosis and management. Clin Gastroenterol Hepatol. 2017;15(2):182–93.CrossRefPubMed Schiller LR, Pardi DS, Sellin JH. Chronic diarrhea: diagnosis and management. Clin Gastroenterol Hepatol. 2017;15(2):182–93.CrossRefPubMed
34.
Zurück zum Zitat Fernández-Bañares F, Esteve M, Viver JM. Fructose-sorbitol malabsorption. Curr Gastroenterol Rep. 2009;11(5):368–74.CrossRefPubMed Fernández-Bañares F, Esteve M, Viver JM. Fructose-sorbitol malabsorption. Curr Gastroenterol Rep. 2009;11(5):368–74.CrossRefPubMed
35.
36.
Zurück zum Zitat Halmos EP, Power VA, Shepherd SJ, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67–75.CrossRefPubMed Halmos EP, Power VA, Shepherd SJ, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67–75.CrossRefPubMed
37.
Zurück zum Zitat Hansen M, Sonne DP, Mikkelsen KH, et al. Bile acid sequestrants for glycemic control in patients with type 2 diabetes: a systematic review with meta-analysis of randomized controlled trials. J Diabetes Complicat. 2017;31(5):918–27.CrossRefPubMed Hansen M, Sonne DP, Mikkelsen KH, et al. Bile acid sequestrants for glycemic control in patients with type 2 diabetes: a systematic review with meta-analysis of randomized controlled trials. J Diabetes Complicat. 2017;31(5):918–27.CrossRefPubMed
38.
Zurück zum Zitat Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2008;104:S1–S35.CrossRef Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2008;104:S1–S35.CrossRef
39.
Zurück zum Zitat Fedorak RN. Treatment of diabetic diarrhea with clonidine. Ann Intern Med. 1985;102(2):197–9.CrossRefPubMed Fedorak RN. Treatment of diabetic diarrhea with clonidine. Ann Intern Med. 1985;102(2):197–9.CrossRefPubMed
40.
Zurück zum Zitat Fragkos KC, Zárate-Lopez N, Frangos CC. What about clonidine for diarrhoea? A systematic review and meta-analysis of its effect in humans. Ther Adv Gastroenterol. 2016;9(3):282–301.CrossRef Fragkos KC, Zárate-Lopez N, Frangos CC. What about clonidine for diarrhoea? A systematic review and meta-analysis of its effect in humans. Ther Adv Gastroenterol. 2016;9(3):282–301.CrossRef
41.
Zurück zum Zitat Bretzke G. Therapy of diarrhea in diabetic enteropathy with clonidine. Z Gesante Inn Med. 1987;42:680–2. Bretzke G. Therapy of diarrhea in diabetic enteropathy with clonidine. Z Gesante Inn Med. 1987;42:680–2.
42.
Zurück zum Zitat Morali GA, Braverman DZ, Lissi J, et al. Effect of clonidine on gallbladder contraction and small bowel transit time in insulin-treated diabetics. Am J Gastroenterol. 1991;86(8):995–9.PubMed Morali GA, Braverman DZ, Lissi J, et al. Effect of clonidine on gallbladder contraction and small bowel transit time in insulin-treated diabetics. Am J Gastroenterol. 1991;86(8):995–9.PubMed
43.
Zurück zum Zitat Mourad FH, Gorard D, Thillainayagam AV, et al. Effective treatment of diabetic diarrhoea with somatostatin analogue, octreotide. Gut. 1992;33(11):1578–80.CrossRefPubMedPubMedCentral Mourad FH, Gorard D, Thillainayagam AV, et al. Effective treatment of diabetic diarrhoea with somatostatin analogue, octreotide. Gut. 1992;33(11):1578–80.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Nakabayashi H. Marked improvement of diabetic diarrhea with the somatostatin analogue octreotide. Arch Intern Med. 1994;154(16):1863–7.CrossRefPubMed Nakabayashi H. Marked improvement of diabetic diarrhea with the somatostatin analogue octreotide. Arch Intern Med. 1994;154(16):1863–7.CrossRefPubMed
46.
Zurück zum Zitat Murao S, Hosokawa H. Serotonin 5-HT3 receptor antagonist for treatment of severe diabetic diarrhea. Diabetes Care. 2010;33(3):e38.CrossRefPubMed Murao S, Hosokawa H. Serotonin 5-HT3 receptor antagonist for treatment of severe diabetic diarrhea. Diabetes Care. 2010;33(3):e38.CrossRefPubMed
47.
Zurück zum Zitat Bossi A, Baresi A, Ballini A, et al. Ondasentron in the treatment of diabetic diarrhea. Diabetes Care. 1994;17(5):453–4.CrossRefPubMed Bossi A, Baresi A, Ballini A, et al. Ondasentron in the treatment of diabetic diarrhea. Diabetes Care. 1994;17(5):453–4.CrossRefPubMed
48.
Zurück zum Zitat Lee TH, Lee JS. Ramosetron might be useful for treating diabetic diarrhea with a rapid small bowel transit time. Korean J Intern Med. 2013;28(1):106–7.CrossRefPubMed Lee TH, Lee JS. Ramosetron might be useful for treating diabetic diarrhea with a rapid small bowel transit time. Korean J Intern Med. 2013;28(1):106–7.CrossRefPubMed
49.
Zurück zum Zitat Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63(10):1617–25.CrossRefPubMed Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63(10):1617–25.CrossRefPubMed
50.
Zurück zum Zitat Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300(23):2754–64.CrossRefPubMedPubMedCentral Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300(23):2754–64.CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat de Kort S, Masclee AA, Sanduleanu S, et al. Higher risk of colorectal cancer in patients with newly diagnosed diabetes mellitus before the age of colorectal cancer screening initiation. Sci Rep. 2017;7:46527.CrossRefPubMedPubMedCentral de Kort S, Masclee AA, Sanduleanu S, et al. Higher risk of colorectal cancer in patients with newly diagnosed diabetes mellitus before the age of colorectal cancer screening initiation. Sci Rep. 2017;7:46527.CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr. 2007;86(3):836S–42S. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr. 2007;86(3):836S–42S.
53.
Zurück zum Zitat González N, Prieto I, del Puerto-Nevado L, et al. 2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications. Oncotarget. 2017;8(11):18456–85.PubMedPubMedCentral González N, Prieto I, del Puerto-Nevado L, et al. 2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications. Oncotarget. 2017;8(11):18456–85.PubMedPubMedCentral
54.
Zurück zum Zitat Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607.CrossRefPubMed Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607.CrossRefPubMed
55.
Zurück zum Zitat Giovannuci E, Harlan DM, Arhcer MC, et al. Diabetes and cancer. A consensus report. CA Cancer J Clin. 2010;60(4):207–21.CrossRef Giovannuci E, Harlan DM, Arhcer MC, et al. Diabetes and cancer. A consensus report. CA Cancer J Clin. 2010;60(4):207–21.CrossRef
56.
57.
Zurück zum Zitat Reinmuth N, Liu W, Fan F, et al. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogensis of colon cancer. Clin Canc Res. 2002;8(10):3259–69. Reinmuth N, Liu W, Fan F, et al. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogensis of colon cancer. Clin Canc Res. 2002;8(10):3259–69.
58.
Zurück zum Zitat Meyerhardt JA, Catalano PJ, Haller DG, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2016;21(3):433–40.CrossRef Meyerhardt JA, Catalano PJ, Haller DG, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2016;21(3):433–40.CrossRef
59.
Zurück zum Zitat Stein KB, Snyder CF, Barone BB, et al. Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis. Dig Dis Sci. 2010;55(7):1839–51.CrossRefPubMedPubMedCentral Stein KB, Snyder CF, Barone BB, et al. Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis. Dig Dis Sci. 2010;55(7):1839–51.CrossRefPubMedPubMedCentral
60.
Zurück zum Zitat Fransgaard T, Thygesen LC, Gögenur I. Metformin increases overall survival in patients with diabetes undergoing surgery for colorectal cancer. Ann Surg Oncol. 2016;23(5):1569–75.CrossRefPubMed Fransgaard T, Thygesen LC, Gögenur I. Metformin increases overall survival in patients with diabetes undergoing surgery for colorectal cancer. Ann Surg Oncol. 2016;23(5):1569–75.CrossRefPubMed
61.
Zurück zum Zitat Paulson EC, Thompson E, Mahmoud N. Surgical site infection and colorectal surgical procedures: a prospective analysis of risk factors. Surg Infect. 2017;18(4):520–6.CrossRef Paulson EC, Thompson E, Mahmoud N. Surgical site infection and colorectal surgical procedures: a prospective analysis of risk factors. Surg Infect. 2017;18(4):520–6.CrossRef
62.
Zurück zum Zitat Franciosi M, Lucisano G, Lapice E, et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013;8(8):e71583.CrossRefPubMedPubMedCentral Franciosi M, Lucisano G, Lapice E, et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013;8(8):e71583.CrossRefPubMedPubMedCentral
63.
Zurück zum Zitat Landman GWD, van Hateren KN, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010;33(2):322–6.CrossRefPubMed Landman GWD, van Hateren KN, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010;33(2):322–6.CrossRefPubMed
64.
Zurück zum Zitat Wu L, Zhu J, Prokop LG, et al. Pharmacologic therapy of diabetes and overall cancer risk and mortality: a meta-analysis of 265 studies. Sci Rep. 2015;5(1):C15. Wu L, Zhu J, Prokop LG, et al. Pharmacologic therapy of diabetes and overall cancer risk and mortality: a meta-analysis of 265 studies. Sci Rep. 2015;5(1):C15.
65.
Zurück zum Zitat Higurashi T, Hosono K, Takahashi H, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol. 2016;17(4):475–83.CrossRefPubMed Higurashi T, Hosono K, Takahashi H, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol. 2016;17(4):475–83.CrossRefPubMed
66.
Zurück zum Zitat Dik VK, LMG M, Hyk M, et al. Predicting inadequate bowel preparation for colonoscopy in participants receiving split-dose bowel preparation: development and validation of a prediction score. Gastrointest Endosc. 2015;81(3):665–72.CrossRefPubMed Dik VK, LMG M, Hyk M, et al. Predicting inadequate bowel preparation for colonoscopy in participants receiving split-dose bowel preparation: development and validation of a prediction score. Gastrointest Endosc. 2015;81(3):665–72.CrossRefPubMed
67.
Zurück zum Zitat Mandolesi D, Frazzoni L, Bazzoli F, et al. The management of “hard-to-prepare” colonoscopy patients. Expert Rev Gastroenterol Hepatol. 2017;93(816):1–10. Mandolesi D, Frazzoni L, Bazzoli F, et al. The management of “hard-to-prepare” colonoscopy patients. Expert Rev Gastroenterol Hepatol. 2017;93(816):1–10.
68.
Zurück zum Zitat Ozturk NA, Gokturk HS, Demir M, et al. The effect of autonomous neuropathy on bowel preparation in type 2 diabetes mellitus. Int J Color Dis. 2009;24(12):1407–12.CrossRef Ozturk NA, Gokturk HS, Demir M, et al. The effect of autonomous neuropathy on bowel preparation in type 2 diabetes mellitus. Int J Color Dis. 2009;24(12):1407–12.CrossRef
69.
Zurück zum Zitat Porter NR, Eberth JM, Samson ME, et al. Peer reviewed: diabetes status and being up-to-date on colorectal cancer screening, 2012 behavioral risk factor surveillance system. Prev Chronic Dis. 2016;13:150391.CrossRef Porter NR, Eberth JM, Samson ME, et al. Peer reviewed: diabetes status and being up-to-date on colorectal cancer screening, 2012 behavioral risk factor surveillance system. Prev Chronic Dis. 2016;13:150391.CrossRef
70.
Zurück zum Zitat Hayes A, Buffum M, Hughes J. Diabetic colon preparation comparison study. Gastroenterol Nurs. 2001;34(5):377–82.CrossRef Hayes A, Buffum M, Hughes J. Diabetic colon preparation comparison study. Gastroenterol Nurs. 2001;34(5):377–82.CrossRef
71.
Zurück zum Zitat Kim YH, Seo EH, Lee JS, et al. Inadequate bowel cleansing efficacy of split-dose polyethylene glycol for colonoscopy in type 2 diabetic patients: a prospective and blinded study. J Clin Gastroenterol. 2017;51(3):240–6.PubMed Kim YH, Seo EH, Lee JS, et al. Inadequate bowel cleansing efficacy of split-dose polyethylene glycol for colonoscopy in type 2 diabetic patients: a prospective and blinded study. J Clin Gastroenterol. 2017;51(3):240–6.PubMed
72.
Zurück zum Zitat Alvarez-Gonzalez MA, Flores-Le Roux JA. Bowel preparation for colonoscopy in diabetic patients. Dis Colon Rectum. 2017;49(2):203–4. Alvarez-Gonzalez MA, Flores-Le Roux JA. Bowel preparation for colonoscopy in diabetic patients. Dis Colon Rectum. 2017;49(2):203–4.
73.
Zurück zum Zitat Panarese A. Bowel preparation in diabetic patients undergoing colonoscopy. Dis Colon Rectum. 2017;49(2):202. Panarese A. Bowel preparation in diabetic patients undergoing colonoscopy. Dis Colon Rectum. 2017;49(2):202.
74.
Zurück zum Zitat Pardi DS. Diagnosis and management of microscopic colitis. Am J Gastroenterol. 2016;112(1):78–85.CrossRefPubMed Pardi DS. Diagnosis and management of microscopic colitis. Am J Gastroenterol. 2016;112(1):78–85.CrossRefPubMed
75.
Zurück zum Zitat Pardi DS, Tremaine WJ, Carrasco-Labra A. American Gastroenterological Association institute technical review on the medical management of microscopic colitis. Gastroenterology. 2016;150(1):247–74.CrossRefPubMed Pardi DS, Tremaine WJ, Carrasco-Labra A. American Gastroenterological Association institute technical review on the medical management of microscopic colitis. Gastroenterology. 2016;150(1):247–74.CrossRefPubMed
76.
Zurück zum Zitat Vigren L, Tysk C, Ström M, et al. Celiac disease and other autoimmune diseases in patients with collagenous colitis. Scand J Gastroenterol. 2013;48(8):944–50.CrossRefPubMed Vigren L, Tysk C, Ström M, et al. Celiac disease and other autoimmune diseases in patients with collagenous colitis. Scand J Gastroenterol. 2013;48(8):944–50.CrossRefPubMed
77.
Zurück zum Zitat Fernández-Bañares F, de Sousa MR, Salas A, et al. Epidemiological risk factors in microscopic colitis: a prospective case–control study. Inflamm Bowel Dis. 2013;19(2):411.PubMed Fernández-Bañares F, de Sousa MR, Salas A, et al. Epidemiological risk factors in microscopic colitis: a prospective case–control study. Inflamm Bowel Dis. 2013;19(2):411.PubMed
78.
Zurück zum Zitat Nguyen GC, Smalley WE, Vege SS, et al. American Gastroenterological Association Institute guideline on the medical management of microscopic colitis. Gastroenterology. 2016;150(1):242–6.CrossRefPubMed Nguyen GC, Smalley WE, Vege SS, et al. American Gastroenterological Association Institute guideline on the medical management of microscopic colitis. Gastroenterology. 2016;150(1):242–6.CrossRefPubMed
80.
Zurück zum Zitat Leeds JS, Hopper AD, Hadjivassiliou M, et al. Inflammatory bowel disease is more common in type 1 diabetes mellitus. Gut. 2011;60(S1):A208.CrossRef Leeds JS, Hopper AD, Hadjivassiliou M, et al. Inflammatory bowel disease is more common in type 1 diabetes mellitus. Gut. 2011;60(S1):A208.CrossRef
81.
Zurück zum Zitat Maconi G, Furfaro F, Sciurti R, et al. Glucose intolerance and diabetes mellitus in ulcerative colitis: pathogenetic and therapeutic implications. World J Gastroenterol. 2014;20(13):3507–15.CrossRefPubMedPubMedCentral Maconi G, Furfaro F, Sciurti R, et al. Glucose intolerance and diabetes mellitus in ulcerative colitis: pathogenetic and therapeutic implications. World J Gastroenterol. 2014;20(13):3507–15.CrossRefPubMedPubMedCentral
82.
Zurück zum Zitat Sehgal R, Berg A, Figueroa R, et al. Risk factors for surgical site infections after colorectal resection in diabetic patients. J Am Coll Surg. 2011;212(1):29–34.CrossRefPubMed Sehgal R, Berg A, Figueroa R, et al. Risk factors for surgical site infections after colorectal resection in diabetic patients. J Am Coll Surg. 2011;212(1):29–34.CrossRefPubMed
83.
Zurück zum Zitat Teslova T, Kim M, Lukin D. Diabetes is associated with worse outcomes in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:S19. Teslova T, Kim M, Lukin D. Diabetes is associated with worse outcomes in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:S19.
84.
Zurück zum Zitat Coakley BA, Divino CM. Identifying factors predictive of surgical-site infections after colectomy for fulminant ulcerative colitis. Am Surg. 2012;78(4):481–4.PubMed Coakley BA, Divino CM. Identifying factors predictive of surgical-site infections after colectomy for fulminant ulcerative colitis. Am Surg. 2012;78(4):481–4.PubMed
85.
Zurück zum Zitat Eliakim-Raz N, Fishman G, Yahav D, et al. Predicting Clostridium difficile infection in diabetic patients and the effect of metformin therapy: a retrospective, case–control study. Eur J Clin Microbiol Infect Dis. 2015;34(6):1201–5.CrossRefPubMed Eliakim-Raz N, Fishman G, Yahav D, et al. Predicting Clostridium difficile infection in diabetic patients and the effect of metformin therapy: a retrospective, case–control study. Eur J Clin Microbiol Infect Dis. 2015;34(6):1201–5.CrossRefPubMed
86.
Zurück zum Zitat Luca MC, Rosu F, Hurmuzache M, et al. Updates in the assessment of risk factors in clostridium difficile infection in patients with infectious diseases. Farmacia. 2016;64(1):112–5. Luca MC, Rosu F, Hurmuzache M, et al. Updates in the assessment of risk factors in clostridium difficile infection in patients with infectious diseases. Farmacia. 2016;64(1):112–5.
87.
Zurück zum Zitat Shakov R, Salazar RS, Kagunye SK, et al. Diabetes mellitus as a risk factor for recurrence of Clostridium difficile infection in the acute care hospital setting. Am J Infect Control. 2011;39(3):194–8.CrossRefPubMed Shakov R, Salazar RS, Kagunye SK, et al. Diabetes mellitus as a risk factor for recurrence of Clostridium difficile infection in the acute care hospital setting. Am J Infect Control. 2011;39(3):194–8.CrossRefPubMed
88.
Zurück zum Zitat Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(S2):1–26.CrossRefPubMed Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(S2):1–26.CrossRefPubMed
Metadaten
Titel
Diabetes Mellitus and the Colon
verfasst von
Marc S. Piper, MD, MSc
Richard J. Saad, MD, MS, FACG
Publikationsdatum
24.10.2017
Verlag
Springer US
Erschienen in
Current Treatment Options in Gastroenterology / Ausgabe 4/2017
Print ISSN: 1092-8472
Elektronische ISSN: 1534-309X
DOI
https://doi.org/10.1007/s11938-017-0151-1

Weitere Artikel der Ausgabe 4/2017

Current Treatment Options in Gastroenterology 4/2017 Zur Ausgabe

Pancreas (V Chandrasekhara, Section Editor)

Diagnosis and Management of Pancreatic Cystic Neoplasms

Motility (H Parkman and R Schey, Section Editors)

Diabetes and the Small Intestine

Pancreas (V Chandrasekhara, Section Editor)

Diagnosis and Management of Autoimmune Pancreatitis

Stomach (DA Johnson, Section Editor)

Endoscopic Treatments for Obesity

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Innere Medizin

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.